ATE478145T1 - Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren - Google Patents

Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren

Info

Publication number
ATE478145T1
ATE478145T1 AT00916675T AT00916675T ATE478145T1 AT E478145 T1 ATE478145 T1 AT E478145T1 AT 00916675 T AT00916675 T AT 00916675T AT 00916675 T AT00916675 T AT 00916675T AT E478145 T1 ATE478145 T1 AT E478145T1
Authority
AT
Austria
Prior art keywords
polypeptides
secreted
nucleic acids
present
acids coding
Prior art date
Application number
AT00916675T
Other languages
English (en)
Inventor
Avi Ashkenazi
Kevin P Baker
David Botstein
Luc Desnoyers
Dan L Eaton
Napoleone Ferrara
Hanspeter Gerber
Mary E Gerritsen
Audrey Goddard
Paulj Godowski
Christipher Grimaldi
Austin Gurney
Ivar J Kljavin
Mary A Napier
James Pan
Nicholas F Paoni
Margaret Ann Roy
Timothy Stewart
Daniel Tumas
Colin Watanabe
P Mickey Williams
William Wood
Zemin Zhang
Sherman Fong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/en
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Priority claimed from PCT/US1999/028301 external-priority patent/WO2000032776A2/en
Priority claimed from PCT/US1999/030095 external-priority patent/WO2000037640A2/en
Priority claimed from PCT/US2000/000219 external-priority patent/WO2000053753A2/en
Priority claimed from PCT/US2000/000376 external-priority patent/WO2000053755A2/en
Priority claimed from PCT/US2000/003565 external-priority patent/WO2001053486A1/en
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/en
Priority claimed from PCT/US2000/004414 external-priority patent/WO2001004311A1/en
Priority claimed from PCT/US2000/004914 external-priority patent/WO2000075327A1/en
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/en
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/en
Priority claimed from PCT/US2000/007377 external-priority patent/WO2001019991A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ATE478145T1 publication Critical patent/ATE478145T1/de
Application granted granted Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
AT00916675T 1999-06-02 2000-03-30 Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren ATE478145T1 (de)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
PCT/US1999/012252 WO1999063088A2 (en) 1998-06-02 1999-06-02 Membrane-bound proteins and nucleic acids encoding the same
US14103799P 1999-06-23 1999-06-23
US14304899P 1999-07-07 1999-07-07
US14475899P 1999-07-20 1999-07-20
US14569899P 1999-07-26 1999-07-26
US14622299P 1999-07-28 1999-07-28
US14939699P 1999-08-17 1999-08-17
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/021547 WO2000015797A2 (en) 1998-09-17 1999-09-15 Compositions and methods for the treatment of immune related diseases
US15866399P 1999-10-08 1999-10-08
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US1999/028301 WO2000032776A2 (en) 1998-12-01 1999-12-01 Secreted amd transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/030095 WO2000037640A2 (en) 1998-12-22 1999-12-16 Compositions and methods for the treatment of tumor
PCT/US2000/000219 WO2000053753A2 (en) 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US2000/000376 WO2000053755A2 (en) 1999-03-08 2000-01-06 Compositions and methods for the treatment of tumor
PCT/US2000/003565 WO2001053486A1 (en) 1999-03-08 2000-02-11 Compositions and methods for the treatment of tumor
PCT/US2000/004341 WO2000053756A2 (en) 1999-03-08 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/004414 WO2001004311A1 (en) 1999-07-07 2000-02-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/004914 WO2000075327A1 (en) 1999-06-02 2000-02-24 Methods and compositions for inhibiting neoplastic cell growth
PCT/US2000/005841 WO2000053758A2 (en) 1999-03-08 2000-03-02 Compositions and methods for the treatment of immune related diseases
PCT/US2000/006884 WO2001005972A1 (en) 1999-07-20 2000-03-15 Compositions and methods for the treatment of immune related diseases
PCT/US2000/007377 WO2001019991A1 (en) 1999-09-15 2000-03-20 Compositions and methods for the treatment of immune related diseases
PCT/US2000/008439 WO2000073454A1 (en) 1999-06-02 2000-03-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Publications (1)

Publication Number Publication Date
ATE478145T1 true ATE478145T1 (de) 2010-09-15

Family

ID=42676646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916675T ATE478145T1 (de) 1999-06-02 2000-03-30 Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren

Country Status (6)

Country Link
EP (1) EP1210418B1 (de)
JP (4) JP2004522402A (de)
AT (1) ATE478145T1 (de)
AU (1) AU3774300A (de)
CA (1) CA2383254A1 (de)
WO (1) WO2000073454A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016318A2 (en) * 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
WO1999009155A1 (en) 1997-08-19 1999-02-25 Human Genome Sciences, Inc. 70 human secreted proteins
US20030130182A1 (en) * 1997-11-05 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU764441B2 (en) 1998-02-09 2003-08-21 Genset S.A. cDNAs encoding secreted proteins
US7160679B1 (en) 1998-05-21 2007-01-09 Diadexus, Inc. Method of diagnosing, monitoring, and staging lung cancer
US7291712B2 (en) 1998-06-25 2007-11-06 Genentech, Inc. Interleukin-8 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7264801B2 (en) 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US20030003507A1 (en) 1999-06-02 2003-01-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2053129A3 (de) 1998-09-02 2009-08-19 Diadexus, Inc. Diagnose-, Überwachungs-, Stadieneinteilungs-, Bildgebungs- und Behandlungsverfahren für verschiedene Krebsarten
AU5447899A (en) * 1998-09-03 2000-03-27 Takeda Chemical Industries Ltd. Novel protein and process for producing the same
US7014996B1 (en) 1998-10-02 2006-03-21 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU2007216683B2 (en) * 1998-12-17 2011-07-14 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
HK1041025A1 (zh) * 1998-12-23 2002-06-28 Corixa Corporation 用於結腸癌的免疫治療和診斷的化合物及其使用方法
US6242419B1 (en) * 1999-03-25 2001-06-05 Genesis Research & Development Corporation Ltd. Compositions isolated from stromal cells and methods for their use
US7083791B2 (en) 1999-03-25 2006-08-01 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1892249A1 (de) * 1999-09-01 2008-02-27 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
EP1220919A2 (de) * 1999-09-29 2002-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Metastase-assoziertes antigen c4.4a
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
AU783473B2 (en) * 1999-12-23 2005-10-27 Zymogenetics Inc. Soluble interleukin-20 receptor
US7122632B2 (en) 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
JP4280444B2 (ja) * 2000-01-06 2009-06-17 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
CA2398603A1 (en) * 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
EP1947182A1 (de) * 2000-02-15 2008-07-23 Amgen Inc. Fibroblastenwachstumsfaktor-23-Moleküle und ihre Verwendung
WO2001064856A2 (en) * 2000-02-28 2001-09-07 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001066596A2 (en) * 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
JP2003531583A (ja) * 2000-03-08 2003-10-28 カイロン コーポレイション ヒトｆｇｆ−２３遺伝子および遺伝子発現産物
EP1283214B1 (de) * 2000-04-21 2007-02-14 Fuso Pharmaceutical Industries Ltd. Neue collectine
AU2001259565A1 (en) * 2000-05-04 2001-11-12 Incyte Genomics, Inc. Proteases
DE60142511D1 (de) * 2000-05-11 2010-08-19 Zymogenetics Inc Zsig33-ähnliche peptide
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
JP2004502417A (ja) * 2000-06-30 2004-01-29 アムジェン　インコーポレーテッド Ｂ７様分子およびその使用
AU2001272735A1 (en) 2000-07-18 2002-01-30 Takeda Chemical Industries Ltd. Novel physiologically active peptide and use thereof
AU2001273323B2 (en) 2000-07-19 2005-11-10 Advanced Research & Technology Institute Novel fibroblast growth factor (FGF23) and methods for use
US20040082506A1 (en) 2000-08-11 2004-04-29 Takeyoshi Yamashita Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
CA2421056A1 (en) * 2000-09-01 2002-03-28 Genentech, Inc. A polypeptide for use as a diagnostic marker for the presence of colon tumours
EP1332157A2 (de) 2000-11-03 2003-08-06 The Regents of the University of California Prokineticin polypeptide, verwandte zusammensetzungen und methoden
CA2433171A1 (en) * 2000-12-26 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Human fgf23 protein mutants decreasing blood phosphorus level
EP1873245A1 (de) * 2001-02-28 2008-01-02 Genentech, Inc. Interleukin-8-homologe Polypeptide und ihre therapeutische Verwendung
EP1881007A1 (de) * 2001-03-27 2008-01-23 Novartis AG LLR-j24 abhängige Proteine
US6734289B2 (en) * 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2003002737A1 (fr) * 2001-06-27 2003-01-09 Riken Nouvelle proteine inhibitrice de la topoisomerase humaine 2$g(a) et utilisation associee
IL159872A0 (en) * 2001-07-26 2004-06-20 Genset Sa Gmg-2 polypeptides and their use
CA2471656C (en) 2001-12-28 2012-07-31 Kirin Beer Kabushiki Kaisha Antibody against fibroblast growth factor-23
WO2003080667A2 (en) * 2002-03-22 2003-10-02 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
AU2002303430A1 (en) * 2002-04-23 2003-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1514940B1 (de) * 2002-05-31 2008-11-19 Seikagaku Corporation Chondroitinsynthetase und das enzym codierende dna
WO2004022087A1 (ja) * 2002-09-04 2004-03-18 Takeda Pharmaceutical Company Limited 疾患関連遺伝子の用途
AU2003277616A1 (en) * 2002-11-07 2004-06-07 National Institute Of Advanced Industrial Science And Technology Method of detecting bone Paget' disease
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
EP1578254B1 (de) 2002-11-19 2013-03-06 DRG International, Inc. Diagnoseverfahren für erkrankungen durchuntersuchung auf hepcidin in menschlichem oder tierischem gewebe, blut oderkörperflüssigkeiten und therapeutische anwendungen dafür
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
CA2515288A1 (en) 2003-03-12 2004-09-23 Genentech, Inc. Compositions with hematopoietic and immune activity
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
ATE395430T1 (de) * 2003-05-28 2008-05-15 Bayer Healthcare Ag Diagnostik- und therapie- verfahren von mit pils verbundenen krankheiten
DE602004024921D1 (de) * 2003-11-17 2010-02-11 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
JP4658967B2 (ja) * 2003-12-24 2011-03-23 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
WO2005068497A1 (en) * 2004-01-06 2005-07-28 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Iis: a novel ifn-gamma-inducible protein, member of the secretoglobin family, that modulates cellular invasion and migration
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2006034189A (ja) * 2004-07-28 2006-02-09 National Institute Of Advanced Industrial & Technology 組織の癌化の検出方法
US7544659B2 (en) 2004-08-13 2009-06-09 Genentech, Inc. Promotion of axonal regeneration
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
NZ568015A (en) 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
CN100460013C (zh) * 2006-09-05 2009-02-11 重庆康卫生物科技有限公司 口服重组幽门螺杆菌疫苗及其制备方法
WO2008042826A2 (en) 2006-09-29 2008-04-10 University Of Maryland, Baltimore Use of omentin 1 and omentin 2 in the diagnosis and treatment of disease
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
AR069062A1 (es) 2007-11-02 2009-12-23 Lilly Co Eli Anticuerpo anti-hepcidina
KR101462307B1 (ko) 2008-08-06 2014-11-17 일라이 릴리 앤드 캄파니 항-헵시딘-25 선택적 항체 및 그의 용도
EP2538973A2 (de) 2010-02-26 2013-01-02 Novo Nordisk A/S Stabile, antikörperhaltige zusammensetzungen
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
RS57393B1 (sr) 2013-03-15 2018-09-28 Hoffmann La Roche Il-22 polipeptiidi i il-22 fuzioni proteini i metode za njihovu upotrebu

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
WO1999063088A2 (en) * 1998-06-02 1999-12-09 Genentech, Inc. Membrane-bound proteins and nucleic acids encoding the same
CA2283299A1 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
JP2002512517A (ja) * 1997-03-25 2002-04-23 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
CA2296287A1 (en) * 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in prostate
DE19811194A1 (de) * 1998-03-10 1999-09-16 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Prostatagewebe
DE19817557A1 (de) * 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Ovartumorgewebe
JPH11332571A (ja) * 1998-05-29 1999-12-07 Taisho Pharmaceut Co Ltd 新規遺伝子とそれにコードされる蛋白質
CA2337904A1 (en) * 1998-08-03 2000-02-17 Novartis Ag Novel genes in control of hematopoiesis
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
EP1173456A4 (de) * 1999-03-01 2005-10-12 Millennium Pharm Inc Sekretierte proteine und sie kodierende nukleinsäuren
CA2373231A1 (en) * 1999-05-19 2000-11-23 Incyte Genomics, Inc. Extracellular signaling molecules
CA2392128A1 (en) * 1999-11-16 2001-05-21 Zymogenetics, Inc. Human zven proteins
EP1572987A4 (de) * 2000-02-03 2005-11-30 Nuvelo Inc Neuartige nukleinsäure und polypeptide

Also Published As

Publication number Publication date
WO2000073454A1 (en) 2000-12-07
EP1210418B1 (de) 2010-08-18
JP5512073B2 (ja) 2014-06-04
EP1210418A1 (de) 2002-06-05
AU3774300A (en) 2000-12-18
JP2007302681A (ja) 2007-11-22
CA2383254A1 (en) 2000-12-07
JP2004522402A (ja) 2004-07-29
JP2004203742A (ja) 2004-07-22
JP4017507B2 (ja) 2007-12-05
JP2011236224A (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
ATE478145T1 (de) Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
ATE448246T1 (de) Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
MXPA01002592A (es) Polipeptidos de transmembrana y secretados y acidos nucleicos que codifican los mismos.
WO2001016318A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001040466A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000053756A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001068848A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008288A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002024888A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR100468977B1 (ko) 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
ATE417063T1 (de) Sekretierte transmembranproteine und dafür kodierende nukleinsäuren
ATE300553T1 (de) Sekretiertes polypeptide und dafür kodierende nukleinsäuren
DE69932266D1 (de) Sekretiertes und transmembranes Polypeptid und dafür kodierende Nukleinsäure
ATE447026T1 (de) Ausgeschiedene und transmembrane polypeptide und dafür kodierende nukleinsäure
ATE363537T1 (de) Ausgeschiedene und transmembranpolypeptide und dafür kodierende nukleinsäure
ATE396201T1 (de) Ausgeschiedene und transmembranpolypeptide und dafür kodierende nukleinsäure
ATE321136T1 (de) Sekretierte und transmembrane polypeptide und dafür kodierende nukleinsäuren
DK1241180T3 (da) Humant A33 antigen-lignende protein og nucleinsyrer, der koder for dette
ATE380864T1 (de) Menschliches prostasin-ähnliches protein und dafür kodierende nukleinsäure
ATE282047T1 (de) Polypeptide und dafür kodierende nukleinsäure
ATE291085T1 (de) Polypeptide und dafür kodierende nukleinsäure
DE69824455D1 (de) PRO241 Polypeptide und dafür kodierende Nukleinsäuren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties